TY - JOUR AU - Vaklavas, Christos AU - Roberts, Brian S. AU - Varley, Katherine E. AU - Lin, Nancy U. AU - Liu, Minetta C. AU - Rugo, Hope S. AU - Puhalla, Shannon AU - Nanda, Rita AU - Storniolo, Anna Maria AU - Carey, Lisa A. AU - Saleh, Mansoor N. AU - Li, Yufeng AU - Delossantos, Jennifer F. AU - Grizzle, William E. AU - LoBuglio, Albert F. AU - Myers, Richard M. AU - Forero-Torres, Andres AU - on behalf of the Translational Breast Cancer Research Consortium (TBCRC) PY - 2020 DA - 2020/02/18 TI - TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer JO - Breast Cancer Research SP - 22 VL - 22 IS - 1 AB - In preclinical studies, the expression of vascular endothelial growth factor (VEGF) in hormone receptor-positive breast cancer is associated with estrogen-independent tumor growth and resistance to endocrine therapies. This study investigated whether the addition of bevacizumab, a monoclonal antibody against VEGF, to letrozole enhanced the antitumor activity of the letrozole in the preoperative setting. SN - 1465-542X UR - https://doi.org/10.1186/s13058-020-01258-x DO - 10.1186/s13058-020-01258-x ID - Vaklavas2020 ER -